Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference

Rhea-AI Summary

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) will participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference from February 22 to 26, 2021. Dinesh V. Patel, Ph.D., President and CEO, is scheduled for a fireside chat on February 24, 2021, at 10:40 a.m. EST. The event will be available for live and archived viewing on the company’s website. Protagonist, based in Newark, California, focuses on innovative peptide-based therapeutics, with several candidates in clinical trials for conditions like Crohn's disease and polycythemia vera.

NEWARK, Calif., Feb. 16, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place February 22 to February 26, 2021.

Fireside chat details:
Date: Wednesday, February 24, 2021
Time: 10:40 a.m. EST

A live and archived webcast of the event will be available at https://wsw.com/webcast/svbleerink47/ptgx/2693120 and on the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development. PTG-300 is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis. PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease. Two additional oral peptide interleukin-23 receptor antagonist candidates are in development: PN-235, in a Phase 1 study, and PN-232, in the late preclinical stage. PN-943 is an orally delivered, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide in a Phase 2 study for the potential treatment of inflammatory bowel disease, with ulcerative colitis as the initial targeted indication. The Company utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms.

Protagonist is headquartered in Newark, California. For further information, please visit http://www.protagonist-inc.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-participate-in-the-svb-leerink-virtual-10th-annual-global-healthcare-conference-301227755.html

SOURCE Protagonist Therapeutics, Inc.

FAQ

When is Protagonist Therapeutics participating in the SVB Leerink Virtual Conference?

Protagonist Therapeutics will participate from February 22 to 26, 2021.

What is the date and time of the fireside chat featuring Dinesh V. Patel?

The fireside chat is on February 24, 2021, at 10:40 a.m. EST.

How can I watch the Protagonist Therapeutics fireside chat?

The fireside chat will be available for live and archived viewing on the Protagonist Therapeutics website.

What are the key products in development by Protagonist Therapeutics?

Protagonist has multiple candidates including PTG-300 for polycythemia vera and PTG-200 for Crohn's disease.

Where is Protagonist Therapeutics headquartered?

Protagonist Therapeutics is headquartered in Newark, California.